Adalvo have successfully launched the first-to-market Lisdexamfetamine Oral Solution in Germany, achieved in collaboration with our strategic partner, Aristo Pharma, and co-developers, Labomed and Pharmadata. The formulation is protected by a granted European Patent.
The launch takes place following the revocation of the SPC by the Federal Patent Court (appeal pending), and reflects Adalvo’s focused IP strategy and strong supply chain capabilities, ensuring high-quality, timely product launches.
Lisdexamfetamine Oral Solution is a ready-to-use, child-friendly formulation indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). According to IQVIA, Lisdexamfetamine INN achieved global sales of $6.1bn in 2023.
Outside of Europe, Adalvo's ANDA filing for Lisdexamfetamine Oral Solution was officially accepted by the US FDA, marking a key step forward in bringing this therapy to one of the world’s largest healthcare markets.
At Adalvo, there are no half-measures – we are always on target. When your mission is to outpace and outperform your competition, you need a winning team driving your vision forward.
Partner up now!